Broad Sell-Off Nails Biotech Stocks As Well…Update-1
Update-1... 3/19. Close is off the lows for Biotech Indices QQQ gap down to $167.10 also at SMA 50 XBI at SMA 50 bottom of channel at $91.89 XLV at $84 approaching February lows of $81 It is very difficult to find news or trends that can help us navigate this sell-off where macro news not...
Weak NASDAQ Leaves Biotech Stocks Stalled…Update-1
Update-1 ...March 18- Market jittery on potential global trade war, rising interest rate concerns and political risk. Also Sales to U.S. retailers fell 0.1% in February a 3 month slide. Biotechs are in a risk-off mode with a weak tape. Dow down 0.47%, NASDAQ down 0.2%, IBB down 0.98%, XBI down...
Biotechs Buffeted by Macro News But Should Continue to Outperform…Update-1
Update-1 March 10... Broad Rally Continues Through The Week QQQ Up 4.3% IBB up 4.3% XBI up 4.8% Gene Editing Stocks Surge Biotech stocks soared along with the market as fear about interest rates, tariffs and global politics subsided helped considerably by economic sentiment and jobs. Moreover...
Sluggish Tape And Possibly An End to Celgene Woes?…Update
Update after close 2/28/18 Tape deteriorates at last hour of trading, a familiar pattern: IBB down 1.83%, QQQ down 0.64%, XBI down 1.88% for day. Biotechs still up YTD with XBI;FBT down 2.35% but still up 8.28% YTD. Celgene, Inc (CELG) sell-off continues down 9% to $87.12 on 27.87M share...
Large Cap Biopharmaceuticals Performance Update 2018: Part 2
Large Cap Biopharmaceuticals: Winners and Losers, Takeaways Here is a brief analysis from data below. Data Sources : Google Finance and FinViz.com. Our Top Picks continue to do well: Abbvie (ABBV), Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD). Laggards in our focus group are Biogen...